Cargando…
Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells
Cancer stem cells (CSCs) are believed to be a principal cellular source for tumour progression and therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer cells. Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667417/ https://www.ncbi.nlm.nih.gov/pubmed/29109790 http://dx.doi.org/10.7150/thno.20725 |
_version_ | 1783275482649722880 |
---|---|
author | Zhou, Gang Latchoumanin, Olivier Bagdesar, Mary Hebbard, Lionel Duan, Wei Liddle, Christopher George, Jacob Qiao, Liang |
author_facet | Zhou, Gang Latchoumanin, Olivier Bagdesar, Mary Hebbard, Lionel Duan, Wei Liddle, Christopher George, Jacob Qiao, Liang |
author_sort | Zhou, Gang |
collection | PubMed |
description | Cancer stem cells (CSCs) are believed to be a principal cellular source for tumour progression and therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer cells. Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through changes at the genetic, epigenetic and micro-environment levels. Therefore, therapeutic strategies targeting CSCs hold great potential as an avenue for cancer treatment. Aptamers or “chemical antibodies” are a group of single-stranded nucleic acid (DNA or RNA) oligonucleotides with distinctive properties such as smaller size, lower toxicity and less immunogenicity compared to conventional antibodies. They have been frequently used to deliver therapeutic payloads to cancer cells and have achieved encouraging anti-tumour effects. This review discusses progress in CSC evolution theory and the role of aptamers to target CSCs for cancer treatment. Challenges of aptamer-mediated CSC targeting approaches are also discussed. |
format | Online Article Text |
id | pubmed-5667417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-56674172017-11-06 Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells Zhou, Gang Latchoumanin, Olivier Bagdesar, Mary Hebbard, Lionel Duan, Wei Liddle, Christopher George, Jacob Qiao, Liang Theranostics Review Cancer stem cells (CSCs) are believed to be a principal cellular source for tumour progression and therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer cells. Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through changes at the genetic, epigenetic and micro-environment levels. Therefore, therapeutic strategies targeting CSCs hold great potential as an avenue for cancer treatment. Aptamers or “chemical antibodies” are a group of single-stranded nucleic acid (DNA or RNA) oligonucleotides with distinctive properties such as smaller size, lower toxicity and less immunogenicity compared to conventional antibodies. They have been frequently used to deliver therapeutic payloads to cancer cells and have achieved encouraging anti-tumour effects. This review discusses progress in CSC evolution theory and the role of aptamers to target CSCs for cancer treatment. Challenges of aptamer-mediated CSC targeting approaches are also discussed. Ivyspring International Publisher 2017-09-13 /pmc/articles/PMC5667417/ /pubmed/29109790 http://dx.doi.org/10.7150/thno.20725 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Zhou, Gang Latchoumanin, Olivier Bagdesar, Mary Hebbard, Lionel Duan, Wei Liddle, Christopher George, Jacob Qiao, Liang Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells |
title | Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells |
title_full | Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells |
title_fullStr | Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells |
title_full_unstemmed | Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells |
title_short | Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells |
title_sort | aptamer-based therapeutic approaches to target cancer stem cells |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667417/ https://www.ncbi.nlm.nih.gov/pubmed/29109790 http://dx.doi.org/10.7150/thno.20725 |
work_keys_str_mv | AT zhougang aptamerbasedtherapeuticapproachestotargetcancerstemcells AT latchoumaninolivier aptamerbasedtherapeuticapproachestotargetcancerstemcells AT bagdesarmary aptamerbasedtherapeuticapproachestotargetcancerstemcells AT hebbardlionel aptamerbasedtherapeuticapproachestotargetcancerstemcells AT duanwei aptamerbasedtherapeuticapproachestotargetcancerstemcells AT liddlechristopher aptamerbasedtherapeuticapproachestotargetcancerstemcells AT georgejacob aptamerbasedtherapeuticapproachestotargetcancerstemcells AT qiaoliang aptamerbasedtherapeuticapproachestotargetcancerstemcells |